MERCK KGAA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 165.7 EUR | -0.51% |
|
+7.25% | +14.99% |
| 16/05 | MERCK KGAA : DZ Bank gives a Buy rating | ZD |
| 16/05 | MERCK KGAA : Gets a Buy rating from Barclays | ZD |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 2.12TCr 2.31TCr 1,92000Cr | Sales 2025 * | 2.25TCr 2.44TCr 2,03000Cr | Capitalization | 7.2TCr 7.82TCr 6,51000Cr |
|---|---|---|---|---|---|
| Net income 2024 * | 298.2Cr 323.71Cr 27TCr | Net income 2025 * | 347.6Cr 377.33Cr 31TCr | EV / Sales 2024 * | 3.39 x |
| Net cash position 2024 * | - 0 0 | Net Debt 2025 * | 4.49T 4.87T 4L | EV / Sales 2025 * | 3.21 x |
| P/E ratio 2024 * |
23.9
x | P/E ratio 2025 * |
20.3
x | Employees | 62,345 |
| Yield 2024 * |
1.37% | Yield 2025 * |
1.46% | Free-Float | 29.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Merck KGaA
More press releases
More news
| 1 day | -0.51% | ||
| 1 week | +7.25% | ||
| Current month | +11.25% | ||
| 1 month | +13.49% | ||
| 3 months | +8.02% | ||
| 6 months | +2.89% | ||
| Current year | +14.99% |
1 week
161.30
169.05
1 month
146.10169.05
Current year
140.50169.05
1 year
134.30172.40
3 years
134.30231.50
5 years
76.22231.50
10 years
61.05231.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 13/20/13 | |
Marcus Kuhnert
DFI | Director of Finance/CFO | 56 | 01/14/01 |
| Director of Finance/CFO | 53 | 26/19/26 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Christian Raabe
BRD | Director/Board Member | - | - |
Jürgen Glaser
BRD | Director/Board Member | 61 | 01/12/01 |
Gabriele Eismann
BRD | Director/Board Member | 62 | 01/91/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.34% | 2 M€ | +13.56% | - | |
| 2.01% | 0 M€ | 0.00% | - | |
| 1.80% | 962 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/24/21 | 165.7 | -0.51% | 228,236 |
| 20/24/20 | 166.6 | -0.39% | 101,255 |
| 17/24/17 | 167.2 | -0.89% | 286,898 |
| 16/24/16 | 168.7 | +1.72% | 498,812 |
| 15/24/15 | 165.8 | +4.77% | 741,893 |
Delayed Quote Xetra, May 21, 2024 at 09:05 pm IST
More quotes
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows:
- solutions and products for scientific and biotechnological research (44.2%);
- pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.;
- performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc.
Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).
Sector
Pharmaceuticals
Calendar
01/08/2024
- Q2 2024 Earnings Call
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
165.7
EUR
Average target price
182.3
EUR
Spread / Average Target
+10.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.99% | 7.86TCr | |
| +9.32% | 894.18Cr | |
| -12.05% | 515.89Cr | |
| +53.66% | 484.51Cr | |
| +11.63% | 419.11Cr | |
| -23.67% | 231.51Cr | |
| +12.07% | 228.73Cr | |
| -32.35% | 219.11Cr | |
| +21.04% | 218.95Cr | |
| -0.50% | 164.41Cr |
- Stock Market
- Equities
- MRK Stock